Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibiotics and collateral damage.

Daryl J Hoban1

  • 1University of Manitoba, Winnipeg, Canada. dhoban@hsc.mb.ca

Clinical Cornerstone
|March 3, 2004
PubMed
Summary
This summary is machine-generated.

Antibiotic therapy can disrupt the delicate balance of the human gut microbiome. Understanding these collateral effects is crucial for improving clinical trials and patient health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical And Bacteriological Impact Of Clarithromycin In Streptococcal Pharyngitis: Findings From A Meta-Analysis Of Clinical Trials.

Drug design, development and therapy·2019
Same author

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

The Journal of antimicrobial chemotherapy·2019
Same author

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

The Journal of antimicrobial chemotherapy·2019
Same author

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

The Journal of antimicrobial chemotherapy·2019
Same author

Characterization of MRSA in Canada from 2007 to 2016.

The Journal of antimicrobial chemotherapy·2019
Same author

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

The Journal of antimicrobial chemotherapy·2019
Same journal

Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.

Clinical cornerstone·2009
Same journal

Guiding clinical decisions on abdominal obesity and cardiometabolic risk.

Clinical cornerstone·2009
Same journal

Overweight and obesity: the pathogenesis of cardiometabolic risk.

Clinical cornerstone·2009
Same journal

Obesity as a disease state: a new paradigm for diagnosis and treatment.

Clinical cornerstone·2009
Same journal

Pathogenesis of cardiometabolic risk as it relates to overweight and obesity. Introduction.

Clinical cornerstone·2009
Same journal

Should clinicians routinely determine rhinitis subtype on initial diagnosis and evaluation? A debate among experts.

Clinical cornerstone·2009
See all related articles

Area of Science:

  • Microbiology
  • Ecology
  • Pharmacology

Background:

  • The human gastrointestinal tract harbors a complex indigenous flora crucial for health.
  • This delicate microbial ecosystem is susceptible to disruption from various factors, notably antibiotic treatments.

Purpose of the Study:

  • To explore recent insights into the collateral and ecological effects of antibiotics on the human microbiome.
  • To understand the potential consequences of antibiotic-induced microbiome alterations.

Main Methods:

  • Literature review of recent studies on antibiotic impact on microbial flora.
  • Analysis of ecological consequences and clinical implications.

Main Results:

  • Antibiotic therapy frequently disturbs the normal indigenous flora of the human gastrointestinal tract.

Related Experiment Videos

  • Emerging data highlight significant collateral and ecological effects of antibiotics on the human microbiome.

    • Conclusions:

    • Further research is needed to fully comprehend the consequences of antibiotic-induced microbiome disruption.
    • New data will aid in designing improved clinical trials and addressing collateral damage from antibiotic use.